Biotechnology
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10...
2026-08-10 17:36
1
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), i...
2026-08-10 12:05
948
2026 Global Health Summit Opens in Hong Kong -- Global Healthcare Leaders Convene: Bringing Breakthroughs to Patients
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- The 2026 Global Health Summit ("GHS 2026"), jointly hosted by New Frontier Group ("New Frontier") and the Hong Kong Investment Corporation Limited ("HKIC"), opened today at the Hong Kong Convention and Exhibition Centre for a two-day programme. Held under ...
2026-08-10 11:00
546
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
SHANGHAI, Aug. 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site inspect...
2026-08-10 08:00
1226
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX e...
2026-08-08 15:46
2946
Alebund's AP301 NDA Accepted for Review by China's NMPA
SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatmen...
2026-08-07 18:40
1561
CityUHK ranked No.1 in Hong Kong in Nature Index 2026 Nanoscience and Nanotechnology Supplement
HONG KONG, Aug. 7, 2026 /PRNewswire/ -- City University of Hong Kong (CityUHK)
has achieved another significant milestone in global research excellence.
Following its earlier achievement of ranking 38th globally and 1st in Hong Kong
in the"Nature Index 2026 Chemistry Supplement"
2026-08-07 17:58
1544
Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China
NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ -- TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026,...
2026-08-07 14:44
1712
Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its Phase II clinical trial evaluating RAG-17, an ...
2026-08-06 19:30
828
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per sha...
2026-08-06 18:46
1564
Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment ...
2026-08-06 16:10
1067
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development
Expanded capabilities across Cortellis portfolio help life sciences
organizations turn trusted intelligence into action and accelerate decision
making across the research and development lifecycle
LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc
2026-08-06 16:00
917
Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
HONG KONG, Aug. 6, 2026 /PRNewswire/ -- Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable de...
2026-08-06 13:17
2771
From Patient to Storyteller: Dale Returns to Shanghai After CAR-T Recovery, Sharing a Journey of Hope
SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- After overcoming stage 4B lymphoma through CAR-T therapy, New Zealand patient Dale has returned to Shanghai—not as a patient seeking treatment, but as a survivor sharing his story. Recently, Dale came back to the city where he received life-changing care, to...
2026-08-06 08:57
1816
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2026-08-06 08:00
2355
Telix to Host R&D Day in New York City on September 22, 2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City. Institutional...
2026-08-06 05:00
1599
NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins...
2026-08-05 21:15
3308
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
CRANBURY, N.J. and SUZHOU,China, Aug. 5, 2026 /PRNewswire/ -- Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA).This milestone qualifies Porton Advanced to undertak...
2026-08-05 20:00
1532
Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
* Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 * Alteogen is eligible to receive up to US$365 million, including an upfront payment and development, regulatory and sales milestone payments * Addition...
2026-08-05 20:00
1924
Leading the Future of Oral Delivery, Lonza Capsugel brings breakthrough Capsule Technologies to the Korean Market at CPHI Korea
Advanced Capsule Technology for Improved Digestive Enzyme Delivery SEOUL, South Korea, Aug. 5, 2026 /PRNewswire/ -- Lonza Capsugel has released new peer-reviewed research showing that its Licaps® DUOCAP® capsule-in-capsule technology can significantly improve the protection and targeted deliv...
2026-08-05 18:39
2224
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 327 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 311 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 299 media titles]
2026-08-06 15:10
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 298 media titles]
2026-08-04 07:00
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 294 media titles]
2026-08-04 14:30
Most Read
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
2026-08-04 07:00
13678
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
11818
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
2026-08-04 06:00
10155
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
2026-08-04 14:30
9813